Probiotyki - efekty zdrowotne

• Autorzy: Nowak A , Slizewska K. , Libudzisz Z. , Socha J.

Warianty tytułu

EN

Probiotics - health effects

• Języki publikacji: PL

Abstrakty

PL

W opracowaniu omówiono korzystne działanie probiotyków na zdrowie człowieka, a szczególnie ich rolę w ograniczaniu ryzyka chorób cywilizacyjnych, takich jak nowotwory, otyłość, alergie. Oddzielny rozdział poświęcono bezpieczeństwu stosowania (spożywania) produktów probiotycznych.

EN

Beneficial effects of probiotics on human health were discussed in this paper, and, in particular, their role in reducing risks of civilization diseases, such as: tumours, obesity, allergies. A separate chapter was devoted to the safety aspects of using (consuming) probiotic products.

Słowa kluczowe

PL

probiotyki; bezpieczenstwo stosowania probiotykow; wlasciwosci zdrowotne; walory zdrowotne; zdrowie czlowieka; choroby czlowieka; choroby cywilizacyjne; nowotwory; otylosc; alergie; biegunki; atopowe zapalenie skory; zapalenie jelita grubego; zespol jelita nadwrazliwego; martwicze zapalenie jelit; leczenie; spozycie zywnosci

• Wydawca: -
• Czasopismo: Żywność Nauka Technologia Jakość
• Rocznik: 2010
• Tom: 17
• Numer: 4
• Opis fizyczny: s.20-36,bibliogr.

Twórcy

autor

Nowak A

• Wydzial Biotechnologii i Nauk o Zywnosci, Politechnika Lodzka, ul.Wolczanska 171/173, 90-924 Lodz

autor

Slizewska K.

autor

Libudzisz Z.

autor

Socha J.

Bibliografia

• [1] Alfaleh K., Bassler D.: Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst. Rev., 2008, 23, CD005496.
• [2] Arvola T., Laiho K., Torkkeli S., Mykka’nen H., Salminen S., Maunula L., Isolauri E.: Prophylactic Lactobacillus GG Reduces Antibiotic-Associated Diarrhea in Children With Respiratory Infections: A Randomized Study. Pediatrics, 1997, 104, 1-4.
• [3] Backhed F., Ding H., Wang T., Hooper L.V., Koh G.Y, Nagy A., Semenkovich C.F, Gordon J.I.: The gut microbiota as an environmental factor that regulates fat storage. PNAS, 2004, 101, 15718-15723.
• [4] Benson A., Pifer R.,. Behrendt C.L., Hooper L.V., Yarovinsky F.: Gut Commensal Bacteria Direct a Protective Immune Response against Toxoplasma gondii. Cell Host Microbe, 2009, 187-196.
• [5] Besselink M.G.H., van Santvoort H.C., Buskens E., Boermeester M.A., van Goor H., Timmerman H.M., Nieuwenhuijs V.B., Bollen T.L., van Ramshorst B., Witteman B.J., Rosman C., Ploeg R.J., Brink M.A., Schaapherder A.F., Dejong C.H., Wahab P.J., van Laarhoven C.J., van der Harst E., van Eijck C.H., Cuesta M.A., Akkermans L.M., Gooszen H.G.: Probiotic prophylaxis in predicted severe acute pancreatitis: a randomized, double-blind, placebo-controlled trial. The Lancet, 2008, 371, 651-659.
• [6] Bibiloni R., Fedorak R.N., Tannock G.W. Madsen K.L., Gionchetti P., Campieri M., De Simone C., Sartor R.B.: VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastrioenterol., 2005, 100, 1539-1546.
• [7] Boonyaritichaikij S., Kuwabara K., Nagano J., Kobayashi K., Koga Y.: Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection. Helicobacter, 2009, 14 (3), 202-207.
• [8] Brenner D.M., Chey W.D.: Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. Rev. Gastroenterol. Disord., 2009, 9 (1), 7-15.
• [9] Canani R.B., Cirillo P., Terrin G., Cesarano L., Spagnuolo M.I., de Vincenzo A., Albano F., Passariello A., de Marco G., Manguso F., Guarino A.: Probiotics for treatment of acute diarrhoea in children: randomized clinical trial of five different preparations. Br. Med. J., 2007, doi:10.1136/bmj.39272.581736.55.
• [10] Cats A., Kuipers E.J., Bosschaert M.A., Pot R.G., Vandenbroucke-Grauls C.M., Kusters J.G.: Effect of frequent consumption of Lactobacillus casei-containing milk drink in Helicobacter pyloricolonized subjects. Alimen. Pharm. Ther., 2003, 17, 429-435.
• [11] Chmielewska A., Ruszczyński M., Szajewska H.: Ocena skuteczności Lactobacillus reuteri ATCC 55730 w leczeniu ostrej biegunki infekcyjnej u dzieci: metaanaliza badań z randomizacją. Ped. Współ. Gastroenterol. Hepatol. Żyw. Dziecka, 2008, 10, 32-36.
• [12] Cremonini F., Di Caro S., Nista E.C. Bartolozzi F., Capelli G., Gasbarrini G., Gasbarrini A.: Metaanalysis: the effect of probiotic administration on antibiotic-associated diarrhea. Aliment. Pharmacol. Ther., 2002, 16, 1461-1467.
• [13] Cukrowska B., Ceregra A., Rosiak I.: Probiotyki w profilaktyce i leczeniu atopowego zapalenia skóry. Zakażenia, 2006, 2, 58-61.
• [14] Cukrowska B., Ceregra A., Rosiak I., Klewicka E., Śliżewska K., Motyl I., Libudzisz Z.: Wpływ probiotycznych szczepów Lactobacillus casei i paracasei na przebieg kliniczny wyprysku atopowego u dzieci z alergią pokarmową na białka mleka krowiego. Ped. Współ. Gastroenterol. Hepatol. Żyw. Dziecka, 2008, 10, 15-18.
• [15] Dani C., Biadaioli R., Bertini G., Martelli E., Rubartelli F.: Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol. Neonate, 2002, 82, 103-108.
• [16] Deshpande G., Rao S., Patole S.: Probiotics prevention of necrotizing enterocolitis in preterm neonates with very low birthweight: a systematic review of randomized controlled trials. Lancet, 2007, 369, 1614-1620.
• [17] Donohue D.C., Salminen S.: Safety of probiotic bacteria. Asia Pac. J. Clin. Nutr., 1996, 5, 25-28.
• [18] Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P.: A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol. Clin. Biol., 2008, 32, 147-152.
• [19] Fan Y.J., Chen S.J., Yu Y.C., Si J.M., Liu B.: A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial. J. Zhejiang Univ. Sci. B., 2006, 7 (12), 987-991.
• [20] FAO: Guidelines for the Evaluation of Probiotics in Food, Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food, Londyn Ontario, Kanada, 30.04. – 1.05. 2002, (http://www.who.int /foodsafety/fs_management/en/probiotic_guidelines.pdf).
• [21] Gionchetti P., Rizzello F., Venturi A.: Oral bacteriotheraphy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterol., 2000, 119, 305-309.
• [22] Guslandi M., Giollo P., Testoni P.A.: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. J. Gastroenterol. Hepatol., 2003, 15, 697-698.
• [23] Henker J., Müller S., Laass M.W., Schreiner A., Schulze J.: Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z. Gastroenterol., 2008, 46 (9), 874-875.
• [24] Hickson M., D’Souza A.L., Muthu N. Rogers T.R., Want S., Rajkumar C., Bulpitt C.J.: Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomized double blind placebo controlled trial. Br. Med. J., 2007, 335 (7610), 80.
• [25] Isolauri E., Arvola T., Sutas Y., Moilanen E., Salminen S.: Probiotics in the management of atopic eczema. Clin. Exp. Allergy, 2000, 30, 1604-1610.
• [26] Kajander K., Myllyluoma E., Rajilić-Stojanović M. Kyrönpalo S., Rasmussen M., Järvenpää S., Zoetendal E.G., de Vos W.M., Vapaatalo H., Korpela R.: Clinical trial: multi-species probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment. Pharmacol. Ther., 2008, 27, 48-57.
• [27] Kaliomaki M., Salminen S., Arvilommi H., Kero P., Koskinen P., Isolauri E.: Probiotics in primary prevention of atopic disease: a randomized placebo – controlled trial. Lancet, 2001, 357, 1076-1079.
• [28] Kaliomaki M., Salminen S., Poussa T., Arvilommi H., Isolauri E.: Probiotics and prevention of atopic disease: 4-year follow-up of randomized placebo – controlled trial. Lancet, 2003, 361, 1869-1871.
• [29] Kim J.Y., Kwon J.H., Ahn S.H., Lee S.I., Han Y.S., Choi Y.O., Lee S.Y., Ahn K.M., Ji G.E.: Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr. Allergy Immunol., 2009, doi: 10.1111/j.1399-3038.2009.00958.
• [30] Kirpich I.A., Solovieva N.V., Leikhter S.N., Shidakova N.A., Lebedeva O.V. Sidorov P.I., Bazhukova T.A., Soloviev A.G., Barve S.S., McClain C.J., Cave M.: Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol, 2008, 42, 675-682.
• [31] Kopp M.V., Hennemuth I., Heinzmann A., Urbanek R.: Randomized, double-blind, placebocontrolled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics, 2008, 121 (4), e850-856.
• [32] Kotowska M., Albrecht P., Szajewska H.: Saccharomyces boulardii in the prevention of antibioticassociated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment. Pharmacol. Ther., 2005, 21, 583-590.
• [33] Krasse P., Carlsson B., Dahl C., Paulsson A., Nilsson A., Sinkiewicz G.: Decreased gum bleeding and reduced gingivitis by the probiotics Lactobacillus reuteri. Swed. Dent. J., 2006, 30, 55-60.
• [34] Kuisma J., Mentula S., Jarvinen H., Kahri A., Saxelin M., Farkkila M.: Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment. Pharm. Ther., 2003, 17, 509-515.
• [35] Lee H.Y., Park J.H., Seok S.H. Baek M.W., Kim D.J., Lee K.E., Paek K.S., Lee Y., Park J.H.: Human originated bacteria, Lactobacillus rhamnosus PL60 produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim. Biophys. Acta, 2006, 1761, 736-744.
• [36] Ley R.E., Tumbaugh P., Klein S., Gordon J.I.: Human gut microbes associated with obesity. Nature, 2006, 444, 1022-1023.
• [37] Lin H.C., Su B.H., Chen A.C., Lin T.W., Tsai C.H., Yeh T.F. Oh W.: Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics, 2005, 115, 1-4.
• [38] Mach T.: Clinical usefulness of probiotics in inflammatory bowel diseases. J. Physiol. Pharm., 2006, 57 (9S), 23-33.
• [39] Majamaa H., Isolauri E.: Probiotics: a novel approach in the management of food allergy. J. Allergy Clin. Immunol., 1997, 99, 179-185.
• [40] Marteau P., Lemann M., Seksik P. Laharie D., Colombel J.F., Bouhnik Y., Cadiot G., Soulé J.C., Bourreille A., Metman E., Lerebours E., Carbonnel F., Dupas J.L., Veyrac M., Coffin B., Moreau J., Abitbol V., Blum-Sperisen S., Mary J.Y.: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomized, double-blind, placebocontrolled GETAID trial. Gut, 2006, 55, 842-847.
• [41] Miele E., Pascarella F., Gianetti E., Quagelietta L., Baldassano R.N., Staiano A.: Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol., 2009, 104, 437-443.
• [42] Mimura T., Rizzello F., Helwig U. Poggioli G., Schreiber S., Talbot I.C., Nicholls R.J., Gionchetti P., Campieri M., Kamm M.A.: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut, 2004, 53, 108-114.
• [43] Mshvildadze M., Neu J.: Probiotics and prevention of necrotizing enterocolitis. Early Hum. Dev., 2009, doi:10.1016/j.earlhumdev.2009.08.021.
• [44] Niv E., Naftali T., Hallak R., Vaisman N.: The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin. Nutr., 2005, 24 (6), 925-931.
• [45] Nowak A., Arabski M., Libudzisz Z.: Ability of intestinal Lactic Acid Bacteria to bind or/and metabolise indole. Food Technol. Biotechnol., 2008, 46 (3), 299-304.
• [46] Nowak A., Libudzisz Z.: Ability of intestinal lactic bacteria to bind or/and metabolise phenol and p-cresol. Annals Microbiol., 2007, 57 (3), 329-335.
• [47] Nowak A., Libudzisz Z.: Karcynogeny w przewodzie pokarmowym człowieka. Żywność. Nauka. Technologia. Jakość, 2008, 4 (59), 5-21.
• [48] Nowak A., Libudzisz Z.: Karcynogenna aktywność mikroorganizmów jelitowych. Żywność. Nauka. Technologia. Jakość, 2008, 6 (61), 25-39.
• [49] Nowak A., Libudzisz Z.: Ability of probiotic Lactobacillus casei DN 114001 to bind or/and metabolise heterocyclic aromatic amines (HCA) in vitro. Eur. J. Nutr., 2009, 48 (7), 419-427.
• [50] Rafter J., Bennett M., Caderni G., Clune I., Hughes R., Karlsson P.C., Klinder A., O’Riordan M., O’Sullivan G., Pool-Zobel B., Rechkemmer G., Roller M., Rowland I.R. Salvadori M., Thijs H., Van Loo J., Watzl B., Collins J.K.: Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J. Clin. Nutr., 2007, 85 (2), 488-496.
• [51] Raoult D.: Obesity pandemics and the modification of digestive bacterial flora. Eur. J. Clin. Microbiol. Infect. Dis., 2008, 27, 631-634.
• [52] Rowland I.R.: The role of the gastrointestinal microbiota in colorectal cancer. Curr. Pharm. Des., 2009, 15, 1524-1527.
• [53] Salazar-Lindo E., Miranda-Langschwager P., Campos-Sanchez M., Chea-Woo E., Sack R.B.: Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: a randomized, double-blind, placebo controlled clinical trial. BMC Pediatr., 2004, 4, 18, doi:10.1186/1471-2431-4-18.
• [54] Sazawal S., Hiremath G., Dhingra U., Malik P., Deb S., Black R.E.: Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect. Dis., 2006, 6, 374–82.
• [55] Sood A., Midha V., Makharia G.K., Ahuja V., Singal D., Goswami P., Tandon R.K.: The Probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol., 2009, doi:10.1016/j.cgh.2009.07.016.
• [56] Szajewska H., Mrukowicz J.Z.: Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: A sSystematic review of published randomized, double-blind, placebocontrolled trial. J. Ped. Gastroenterol. Nutr., 2001, 33, S17-S25.
• [57] Szajewska H., Skórka A., Ruszczyński M., Gieruszczak-Białek D.: Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment. Pharmacol. Ther., 2007, 25, 871–881.
• [58] Tennyson C.A., Friedman G.: Microecology, obesity and probiotics. Curr. Opin. Endocrinol. Diabetes Obes., 2008, 15 (5), 422-427.
• [59] Tilg H., Moschen A.R., Kaser A.: Obesity and the microbiota. Gastroenterol., 2009, 136, 1476-1483.
• [60] Tong J.L., Ran Z.H., Shen J., Zhang C.X., Xiao S.D.: Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment. Pharmacol. Ther., 2007, 25, 155–168.
• [61] Turnbaugh P.J., Ridaura V.K., Faith J.J., Rey F.E., Gordon J.I., Knight R.: The effect of diet on the human gut microbiome: A metagenomic analysis in humanized gnotobiotic mice. Science Translational Med., 2009, 1, doi: 10.1126/scitranslmed.3000322
• [62] van Loo J., Clune Y., Bennett M., Collins J.K.: The SYNCAN project: goals, set-up, first results and settings of the human intervention study. Br. J. Nutr., 2005, 93 (1S), S91-98.
• [63] Vanderhoof J.A., Whitney D.B., Antonson D.L., Hanner T.L., Lupo J.V., Young R.J.: Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children J. Pediatr., 1999, 135 (5), 564-568.
• [64] van Niel C.W., Feudtner C., Garrison M.M., Christakis D.A.: A Lactobacillus therapy for acute infectious diarrhea in children: Meta-analysis. Pediatrics, 2002, 109, 678-684.
• [65] Vasiljevic T., Shah N.P.: Probiotics – from Metchnikoff to bioactives. Int. Dairy J., 2008, 18, 714-728.
• [66] Wang K.Y., Li S.N., Liu C.S., Perng D.S., Su Y.C., Wu D.C. Jan C.M., Lai C.H., Wang T.N., Wang W.M.: Effects of ingesting Lactobacillus and Bifidobacterium-containing yoghurt in subjects with colonized Helicobacter pylori. Am. J. Clin. Nutr., 2004, 80, 737-741.
• [67] Zocco M.A., Zireli Dal Verme L., Armuzzi A.: Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn’s disease. Gastroenterol., 2003, 124 (1S), A201.
• [68] Probiotics may ease anxiety: Pilot study - http://www.nutraingredients.com
• [69] Synbiotics and Cancer Prevention Projects http://www.syncan.be
• [70] ISAPP response to Utrecht warming about probiotics - http://www.isapp.net
• [71] Nutrition and Health claims - http://www.efsa.europa.eu/en/faqs/faqnutrition.htm